Pharmacological treatment options for prevention of alcohol relapse;Pharmakologische therapieoptionen zur prävention des alkoholrückfalls

Fortschritte der Neurologie Psychiatrie

Volumn 76, Issue 7, 2008, Pages 421-428

  Heberlein, Annemarie ^a   Bleich, S ^a   Kornhuber, J ^a   Hillemacher, T ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Alcohol addiction; Alcohol withdrawal; Craving; Pharmacotherapy; Relapse prevention

Indexed keywords

5 (4 BROMOPHENYL) 1 (2,4 DICHLOROPHENYL) 4 ETHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ACAMPROSATE; BACLOFEN; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; DISULFIRAM; ENDOCANNABINOID; FLUOXETINE; LITHIUM; MEMANTINE; NALTREXONE; NEFAZODONE; ONDANSETRON; PLACEBO; RIMONABANT; RITANSERIN; SERTRALINE; TOPIRAMATE; VALPROIC ACID;

ALCOHOLISM; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NEUROBIOLOGY; NEUROTRANSMISSION; OFF LABEL DRUG USE; RECEPTOR BLOCKING; RELAPSE; REVIEW; SEROTONINERGIC SYSTEM; WITHDRAWAL SYNDROME;

ALCOHOL DETERRENTS; ALCOHOLISM; EXCITATORY AMINO ACID AGENTS; GABA AGENTS; HUMANS; RECURRENCE; SEROTONIN AGENTS;

EID: 49949112564     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1038220     Document Type: Review

References (117)

1. Mann K. Neue ärztliche Aufgaben bei Alkoholproblemen. Dtsch Ärztebl 2002; 99: 632-644
2. Diehl A, Mann K. Pharmakologische Rückfallprävention bei Alkohol und Tabakabhängigkeit. Internist (Berl) 2007; 48: 79-84, 86-88
3. Kiefer F, Mann K. Diagnostik und Therapie der Alkoholabhä ngigkeit. Fortschr Neurol Psychiatr 2007; 75: 33-46
4. Addolorato G, Abenavoli L, Leggio L et al. How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review. Neuropsychobiology 2005; 51: 59-66
5. Hillemacher T, Kornhuber J, Bleich S. Neurobiologische Mechanismen und Pharmakologische Behandlungsansätze des Alkohol-Craving. Fortschr Neurol Psychiatr 2007; 75: 26-32
6. Bottlender M, Soyka M. Impact of craving on alcohol relapse during, and 12 months following, outpatient treatment. Alcohol Alcohol 2004; 39: 357-361
7. Bleich S, Sperling W, Wiltfang J et al. Exzitatorische Neurotransmission bei chronischem Alkoholismus. Fortschr Neurol Psychiatr 2003; 71 Suppl 1: S36-44
8. Kiefer F, Mann K. New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence. Eur J Pharmacol 2005; 526: 163-171
9. Tsai GE, Ragan P, Chang R et al. Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry 1998; 155: 726-732
10. Heinz A, Schäfer M, Higley JD et al. Neurobiological correlates of the disposition and maintenance of alcoholism. Pharmacopsychiatry 2003; 36 Suppl 3: S255-258
11. Fadda F, Mosca E, Meloni R et al. Ethanol-stress interaction on dopamine metabolism in the medial prefrontal cortex. Alcohol Drug Res 1985; 6: 449-454
12. Davis WM, Smith SG, Werner TE. Noradrenergic role in the self-administration of ethanol. Pharmacol Biochem Behav 1978; 9: 369-374
13. Weiss F, Porrino LJ. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci 2002; 22: 3332-3337
14. Ulm RR, Volpicelli JR, Volpicelli LA. Opiates and alcohol self-administration in animals. J Clin Psychiatry 1995; 56 Suppl 7: 5-14
15. Bönsch D, Reulbach U, Bayerlein K et al. Elevated alpha synuclein mRNA levels are associated with craving in patients with alcoholism. Biol Psychiatry 2004; 56: 984-986
16. Bönsch D, Greifenberg V, Bayerlein K et al. Alpha-synuclein protein levels are increased in alcoholic patients and are linked to craving. Alcohol Clin Exp Res 2005; 29: 763-765
17. Bönsch D, Lederer T, Reulbach U et al. Joint analysis of the NACP-REP1 marker within the alpha synuclein gene concludes association with alcohol dependence. Hum Mol Genet 2005; 14: 967-971
18. Hillemacher T, Bleich S, Fueling H et al. Evidence of an association of leptin serum levels and craving in alcohol dependence. Psychoneuroendocrinology 2007; 32: 87-90
19. Hillemacher T, Kraus T, Rauh J et al. Role of appetite-regulating peptides in alcohol craving: an analysis in respect to subtypes and different consumption patterns in alcoholism. Alcohol Clin Exp Res 2007; 31: 950-954
20. Hillemacher T, Bayerlein K, Reulbach U et al. Influence of beer, wine and spirits consumption on craving. Addict Biol 2005; 10: 181-186
21. Hillemacher T, Bayerlein K, Wilhelm J et al. Volume intake and craving in alcohol withdrawal. Alcohol Alcohol 2006; 41: 61-65
22. Bayerlein K, Hillemacher T, Reulbach U et al. Alcoholism- associated hyperhomocysteinemia and previous withdrawal seizures. Biol Psychiatry 2005; 57: 1590-1593
23. Hillemacher T, Frieling H, Bayerlein K et al. Biological markers to predict previous alcohol withdrawal seizures: a risk assessment. J Neural Transm 2007; 114: 151-154
24. Bleich S, Degner D, Sperling W et al. Homocysteine as a neurotoxin in chronic alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 453-464
25. Hillemacher T, Reulbach U, Bayerlein K et al. Plasma homocysteine concentrations do not influence craving in alcohol withdrawal. Alcohol 2004; 34: 211-215
26. Verheul R, Brink W van den, Geerlings P. A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol 1999; 34: 197-222
27. Heinz A, Löber S, Georgi A et al. Reward craving and withdrawal relief craving: assessment of different motivational pathways to alcohol intake. Alcohol Alcohol 2003; 38: 35-39
28. Kiefer F, Helwig H, Tarnaske T et al. Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. Eur Addict Res 2005; 11: 83-91
29. Kranzler HR, Kirk J van. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001; 25: 1335-1341
30. Kranzler HR, Koob G, Gastfriend DR et al. Advances in the pharmacotherapy of alcoholism: challenging misconceptions. Alcohol Clin Exp Res 2006; 30: 272-281
31. Garbutt JC, West SL, Carey TS et al. Pharmacological treatment of alcohol dependence: a review of the evidence. Jama 1999; 281: 1318-1325
32. Ehrenreich H, Mangholz A, Schmitt M et al. OLITA: an alternative in the treatment of therapy-resistant chronic alcoholics. First evaluation of a new approach. Eur Arch Psychiatry Clin Neurosci 1997; 247: 51-54
33. Krampe H, Stawicki S, Wagner T et al. Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol Clin Exp Res 2006; 30: 86-95
34. Fuller RK, Branchey L, Brightwell DR et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. Jama 1986; 256: 1449-1455
35. Bottlender M, Köhler J, Soyka M. Effektivität psychosozialer Behandlungsmethoden zur medizinischen Rehabilitation alkoholabhängiger Patienten. Fortschr Neurol Psychiatr 2006; 74: 19-31
36. Rammes G, Mahal B, Putzke J et al. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 2001; 40: 749-760
37. Gewiss M, Heidbreder C, Opsomer L et al. Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol Alcohol 1991; 26: 129-137
38. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004; 28: 51-63
39. Lesch OM, Riegler A, Gutierrez K et al. The European acamprosate trials: conclusions for research and therapy. J Biomed Sci 2001; 8: 89-95
40. Chick J, Anton R, Checinski K et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000; 35: 587-593
41. Volpicelli JR, Alterman Al, Hayashida M et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876-880
42. Volpicelli JR, Rhines KC, Rhines JS et al. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 1997; 54: 737-742
43. Gastpar M, Bonnet U, Boning J et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 2002; 22: 592-598
44. Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2005; 8: 267-280
45. Krystal JH, Cramer JA, Krol WF et al. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345: 1734-1739
46. Kiefer F, Jimenez-Arriero MA, Klein O et al. Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone. Addict Biol 2007; 13: 124-129
47. Volpicelli JR, Clay KL, Watson NT et al. Naltrexone in the treatment of alcoholism: predicting response to naltrexone. J Clin Psychiatry 1995; 56 Suppl 7: 39-44
48. Ray LA, Hutchison KE. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 2004; 28: 1789-1795
49. Oslin DW, Berrettini W, Kranzler HR et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28: 1546-1552
50. Garbutt JC Kranzler HR, O'Malley SS et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. Jama 2005; 293: 1617-1625
51. Monti PM, Rohsenow DJ, Swift RM et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001; 25: 1634-1647
52. Cornelius JR, Salloum IM, Ehler JG et al. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 700-705
53. Pettinati HM, Volpicelli JR, Luck G et al. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 2001; 21: 143-153
54. Tiihonen J, Ryynanen OP, Kauhanen J et al. Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. Pharmacopsychiatry 1996; 29: 27-29
55. Naranjo CA, Bremner KE, Lanctot KL. Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction 1995; 90: 87-99
56. Johnson BA, Jasinski DR, Galloway GP et al. Ritanserin in the treatment of alcohol dependence - a multi-center clinical trial. Ritanserin Study Group. Psychopharmacology (Berl) 1996; 128: 206-215
57. Wiesbeck GA, Weijers HG, Chick J et al. Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group. Alcohol Clin Exp Res 1999; 23: 230-235
58. Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology 1989; 22 Suppl 1: 49-59
59. Kranzler HR, Modesto-Lowe V, Kirk J van. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 2000; 22: 493-503
60. Johnson BA, Campling GM, Griffiths P et al. Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers. Psychopharmacology (Berl) 1993; 112: 142-144
61. Sellers EM, Toneatto T, Romach MK et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994; 18: 879-885
62. Johnson BA, Roache JD, Javors MA et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. Jama 2000; 284: 963-971
63. Kranzler HR, Pierucci-Lagha A, Feinn R et al. Effects of ondansetron in early-versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res 2003; 27: 1150-1155
64. Johnson BA, Cloninger CR, Roache JD et al. Age of onset as a discriminator between alcoholic subtypes in a treatment-seeking outpatient population. Am J Addict 2000; 9: 17-27
65. Johnson BA, Ait-Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res 2000; 24: 737-742
66. Ait-Daoud JV, Johnson BA, Prihoda TJ et al. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psychopharmacology (Berl) 2001; 154: 23-27
67. Dorus W, Ostrow DG, Anton R et al. Lithium treatment of depressed and nondepressed alcoholics. Jama 1989; 262: 1646-1652
68. Mueller TI, Stout RL, Rudden S et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res 1997; 21: 86-92
69. Brady KT, Myrick H, Henderson S et al. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend 2002; 67: 323-330
70. Salloum IM, Cornelius JR, Daley DC et al. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 2005; 62: 37-45
71. Claudine AM, de Oliveira IR, Appolinario JC et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry 2007; 68: 1324-1332
72. McElroy SL, Hudson JI, Capece JA et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 2007; 61: 1039-1048
73. Ait-Daoud N, Malcolm JrRJ, Johnson BA. An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addict Behav 2006; 31: 1628-1649
74. Johnson BA, Swift RM, Ait-Daoud N et al. Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on antiepileptics. Alcohol Clin Exp Res 2004; 28: 295-301
75. Johnson BA. Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: a new vista for the treatment of comorbid alcohol and nicotine dependence? Addict Behav 2004; 29: 1465-1479
76. Johnson BA, Ait-Daoud N, Bowden CL et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361: 1677-1685
77. Miranda JrR, Mackillop J, Monti PM et al. Effects of Topiramate on Urge to Drink and the Subjective Effects of Alcohol: A Preliminary Laboratory Study. Alcohol Clin Exp Res 2008; block
78. Gong W, Neill DB, Justice JrJB. GABAergic modulation of ventral pallidal dopamine release studied by in vivo microdialysis in the freely moving rat. Synapse 1998; 29: 406-412
79. Kushner SA, Dewey SL, Kornetsky C. Gamma-vinyl GABA attenuates cocaine-induced lowering of brain stimulation reward thresholds. Psychopharmacology (Berl) 1997; 133: 383-388
80. Spanagel R. Die Rolle des glutamatergen Systems bei Alkoholsucht. Fortschr Neurol Psychiatr 2003; 71 Suppl 1: S33-35
81. Römer KD, Bleich S, Kornhuber J. Glutamat - Ein Transmitter im Spannungsfeld zwischen Toxin und Trophin. Fortschr Neurol Psychiatr 2003; 71 Suppl 1: S3-9
82. Colombo G, Agabio R, Carai MA et al. Ability of baclofen in reducing alcohol intake and withdrawal severity: I - Preclinical evidence. Alcohol Clin Exp Res 2000; 24: 58-66
83. Colombo G, Serra S, Brunetti G et al. Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend 2003; 70: 105-108
84. Colombo G, Serra S, Vacca G et al. Suppression by baclofen of the stimulation of alcohol intake induced by morphine and WIN 55,212-2 in alcohol-preferring rats. Eur J Pharmacol 2004; 492: 189-193
85. Colombo G, Agabio R, Lobina C et al. Stimulation of locomotor activity by voluntarily consumed ethanol in Sardinian alcohol-preferring rats. Eur J Pharmacol 1998; 357: 109-113
86. Chester JA, Cunningham CL. Baclofen alters ethanol-stimulated activity but not conditioned place preference or taste aversion in mice. Pharmacol Biochem Behav 1999; 63: 325-331
87. Colombo G, Vacca G, Serra S et al. Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology (Berl) 2003; 167: 221-224
88. Amtrom KK, Cromwell HC, Markowski T et al. Effect of baclofen on alcohol and sucrose self-administration in rats. Alcohol Clin Exp Res 2003; 27: 900-908
89. Liang JH, Chen F, Krstew E et al. The GABA(B) receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcohol-preferring rats. Neuropharmacology 2006; 50: 632-639
90. Maccioni P, Serra S, Vacca G et al. Baclofen-induced reduction of alcohol reinforcement in alcohol-preferring rats. Alcohol 2005; 36: 161-168
91. Addoforato G, Caputo F, Capristo E et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002; 37: 504-508
92. Flannery BA, Garbutt JC, Cody MW et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res 2004; 28: 1517-1523
93. Addolorato G, Caputo F, Capristo E et al. Ability of baclofen in reducing alcohol craving and intake: II - Preliminary clinical evidence. Alcohol Clin Exp Res 2000; 24: 67-71
94. Addolorato G, Caputo F, Capristo E et al. Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med 2002; 112: 226-229
95. Addolorato G, Leggio L, Abenavoli L et al. Suppression of alcohol delirium tremens by baclofen administration: a case report. Clin Neuropharmacol 2003; 26: 258-262
96. Addolorato G, Leggio L, Abenavoli L et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med 2006; 119: 276e13-18
97. Addolorato G, Leggio L, Ferrulli A et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370: 1915-1922
98. Bleich S, Römer K, Wiltfang J et al. Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry 2003; 18: S33-40
99. Kornhuber J, Bormann J, Retz W et al. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 1989; 166: 589-590
100. Krystal JH, Karper LP, Seibyl JP et al. Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214
101. Bienkowski P, Krzascik P, Koros E et al. Effects of a novel uncompetitive NMDA receptor antagonist, MRZ 2/579 on ethanol self-administration and ethanol withdrawal seizures in the rat. Eur J Pharmacol 2001; 413: 81-89
102. Kotlinska J. NMDA antagonists inhibit the development of ethanol dependence in rats. Pol J Pharmacol 2001; 53: 47-50
103. Höfter SM, Danysz W, Spanagel R. Evidence for alcohol anti-craving properties of memantine. Eur J Pharmacol 1996; 314: R1-2
104. Bisaga A, Evans SM. Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology (Berl) 2004; 172: 16-24
105. Krupitsky EM, Neznanova O, Masalov D et al. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiatry 2007; 164: 519-523
106. Evans SM, Levin FR, Brooks DJ et al. A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res 2007; 31: 775-782
107. Basavarajappa BS, Hungund BL. Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 287-299
108. Fattore L, Fadda P, Fratta W. Endocannabinoid regulation of relapse mechanisms. Pharmacol Res 2007; 56: 418-427
109. Rimondini R, Sommer W, Heilig M. A temporal threshold for induction of persistent alcohol preference: behavioral evidence in a rat model of intermittent intoxication. J Stud Alcohol 2003; 64: 445-449
110. Cippitelli A, Bilbao A, Hansson AC et al. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur J Neurosci 2005; 21: 2243-2251
111. Basavarajappa BS, Cooper TB, Hungund BL. Chronic ethanol administration down-regulates cannabinoid receptors in mouse brain synaptic plasma membrane. Brain Res 1998; 793: 212-218
112. Basavarajappa BS, Hungund BL. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N- arachidonoylphosphatidylethanolamine in SK-N-SH cells. J Neurochem 1999; 72: 522-528
113. Wang L, Liu J, Harvey-White J et al. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci USA 2003; 100: 1393-1398
114. Hungund BL, Szakall I, Adam A et al. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem 2003; 84: 698-704
115. Colombo G, Orru A, Lai P et al. The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence. Mol Neurobiol 2007; 36: 102-112
116. Lallemand F, De Witte P. SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats. Alcohol 2006; 39: 125-134
117. Litten RZ, Fertig J, Mattson M et al. Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs 2005; 10: 323-343